MedTrace Logo

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

NCT04779697 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-02-10

Study results available
· View outcomes & findings →

Summary

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Conditions

Interventions

DRUG

GLP-1 analogue - semaglutide

GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks

OTHER

Placebo

Placebo - administered once weekly for a total of 12 weeks

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Ania Jastreboff, MD, PhD · Internal Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology);

  • Rajita Sinha, PhD · Psychiatry; Director Yale Stress Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2024-11-19
Completion
2024-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04779697 on ClinicalTrials.gov